Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Povidone-Iodine for COVID-19: real-time meta analysis of 13 studies
Covid Analysis, June 28, 2022, DRAFT
https://c19pvpi.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mohamed (RCT) 86% 0.14 [0.01-2.21] viral+ 0/5 3/5 Improvement, RR [CI] Treatment Control Choudhury (RCT) 88% 0.12 [0.03-0.50] death 2/303 17/303 Choudhury (RCT) 84% 0.16 [0.09-0.28] hosp. 12/303 77/303 Choudhury (RCT) 96% 0.04 [0.02-0.07] viral+ 8/303 213/303 Guenezan (RCT) 63% 0.37 [0.06-1.63] viral load 12 (n) 12 (n) Elzein (DB RCT) 89% 0.11 [0.01-1.00] viral load 25 (n) 9 (n) Arefin (RCT) 79% 0.21 [0.08-0.54] viral+ 4/27 19/27 Arefin (RCT) 89% 0.11 [0.03-0.41] viral+ 2/27 19/27 Arefin (RCT) 53% 0.47 [0.26-0.85] viral+ 9/27 19/27 Arefin (RCT) 80% 0.20 [0.09-0.44] viral+ 5/27 25/27 Arefin (RCT) 64% 0.36 [0.21-0.62] viral+ 9/27 25/27 Arefin (RCT) 74% 0.26 [0.19-0.37] viral+ 29/135 44/54 Baxter (RCT) 65% 0.35 [0.01-8.27] hosp. 0/37 1/42 OT​1 Baxter (RCT) 79% 0.21 [0.01-4.24] hosp./ER 0/37 2/42 OT​1 Baxter (RCT) 57% 0.43 [0.20-0.94] no recov. 6/27 18/35 OT​1 Baxter (RCT) 37% 0.63 [0.19-2.05] transmission 4/37 6/35 OT​1 Pablo-Marcos 29% 0.71 [0.32-1.56] viral load 31 (n) 40 (n) Pablo-Marcos 9% 0.91 [0.20-4.16] viral load 31 (n) 40 (n) Elsersy (DB RCT) 91% 0.09 [0.01-1.62] hosp. 0/100 5/100 CT​2 Elsersy (DB RCT) 15% 0.85 [0.76-0.96] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 49% 0.51 [0.42-0.62] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 48% 0.52 [0.43-0.63] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 68% 0.32 [0.22-0.49] viral+ 21/100 65/100 CT​2 Elsersy (DB RCT) 90% 0.10 [0.01-0.77] viral+ 1/100 10/100 CT​2 Elsersy (DB RCT) 29% 0.71 [0.62-0.81] viral+ 70/100 99/100 CT​2 Elsersy (DB RCT) 92% 0.08 [0.05-0.14] transmission 12/194 173/227 CT​2 Elsersy (DB RCT) 94% 0.06 [0.03-0.12] transmission 8/194 157/227 CT​2 Seneviratne (RCT) 33% 0.67 [0.50-0.91] viral load 4 (n) 2 (n) Zarabanda (RCT) -27% 1.27 [0.26-6.28] no recov. 3/13 2/11 OT​1 Zarabanda (RCT) -50% 1.50 [0.31-7.30] no recov. 3/11 2/11 OT​1 Zarabanda (RCT) 0% 1.00 [0.19-5.24] viral+ 2/7 2/7 OT​1 Jamir (ICU) 57% 0.43 [0.27-0.69] death 39/163 62/103 ICU patients Ferrer (RCT) 34% 0.66 [0.02-19.0] viral load 9 (n) 12 (n) Seet (CLUS. RCT) 45% 0.55 [0.38-0.80] symp. case 42/735 64/619 OT​1 Seet (CLUS. RCT) 31% 0.69 [0.37-1.01] cases 338/735 433/619 OT​1 povidone-iodine COVID-19 outcomes c19pvpi.com Jun 2022 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors povidone-iodine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit